Impact of Combination Therapy With Caffeine and Naringin on Insulin Resistance and Renal Function in a Nonalcoholic Fatty Liver Disease Rat Model
BioMed Research International · 2026
DOI: 10.1155/bmri/9927792 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, 2026. Verfasst von Mehrasa Azizollahi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran, mui.ac.ir. Hauptthemen laut MEDLINE: Insulin Resistance, Flavanones, Non-alcoholic Fatty Liver Disease, Kidney. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Isfahan University of Medical Sciences.
Abstract (Originalsprache)
Introduction
Chronic kidney disease (CKD) is a major global health concern, and evidence indicates that non‐alcoholic fatty liver disease (NAFLD) independently increases its risk and progression. This connection involves shared pathways such as chronic inflammation, oxidative stress, and insulin resistance, which can worsen renal injury. Caffeine (CAF) and naringin (NAR), with their antioxidant and anti‐inflammatory properties, may provide protective effects on both NAFLD and CKD. This study evaluated the impact of combined CAF and NAR treatment on insulin resistance and renal function in a high‐fat diet (HFD) induced NAFLD rat model. Materials and Methods Thirty‐five male Wistar rats were randomly assigned to five groups (control, HFD, HFD + CAF, HFD + NAR, HFD + CAF + NAR; n = 7 per group). The HFD groups were fed a HFD (51% calories from fat) for 16 weeks, and from Week 10, received oral treatments with CAF (50 mg/kg/day), NAR (12.5 mg/kg/day), or their combination for 6 weeks. Key outcomes, including insulin resistance (HOMA‐IR), renal function (BUN, creatinine, and eGFR), and systemic inflammation (hs‐CRP) were evaluated at the study′s conclusion.
Findings
HFD significantly increased glucose, HOMA‐IR, BUN, and hs‐CRP ( p < 0.0001), as well as insulin and creatinine levels ( p < 0.001), whereas eGFR decreased ( p < 0.01) compared with controls. Treatment with CAF or NAR partially improved these parameters. The combination therapy produced the most pronounced effects, significantly lowering HOMA‐IR and creatinine ( p < 0.0001), BUN and glucose ( p < 0.001), insulin (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran, mui.ac.ir.
- Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, mui.ac.ir.
- Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran, mui.ac.ir.
- Department of Clinical Pharmacy, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran, mui.ac.ir.
ORCID-Profile: Mehrasa Azizollahi, Maedeh Ghasemi, Zahra Nasehi, Mahdi Amani, Fouzieh Zadhoush
Förderung
- Isfahan University of Medical Sciences
Zitieren
APA
Azizollahi, M., Ghasemi, M., Nasehi, Z., Amani, M., & Zadhoush, F. (2026). Impact of Combination Therapy With Caffeine and Naringin on Insulin Resistance and Renal Function in a Nonalcoholic Fatty Liver Disease Rat Model. BioMed Research International. https://doi.org/10.1155/bmri/9927792
Vancouver
Azizollahi M, Ghasemi M, Nasehi Z, Amani M, Zadhoush F. Impact of Combination Therapy With Caffeine and Naringin on Insulin Resistance and Renal Function in a Nonalcoholic Fatty Liver Disease Rat Model. BioMed Research International. 2026. doi:10.1155/bmri/9927792
BibTeX
@article{Azizollahi2026,
author = {Azizollahi, Mehrasa and Ghasemi, Maedeh and Nasehi, Zahra and Amani, Mahdi and Zadhoush, Fouzieh},
title = {Impact of Combination Therapy With Caffeine and Naringin on Insulin Resistance and Renal Function in a Nonalcoholic Fatty Liver Disease Rat Model},
journal = {BioMed Research International},
year = {2026},
doi = {10.1155/bmri/9927792}
}
EUVIMED